Global Systemic Scleroderma Treatment Market Size study, by Drug Class (Immunosuppressors, Phosphodiesterase 5 inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers and Others), and Regional Forecasts 2021-2027

BIZ4599952
200 Pages
July 2021
Medical Devices

Download Sample Get Discount

Global Systemic Scleroderma Treatment Market is valued approximately at USD 1.46 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 4% over the forecast period 2021-2027. Systemic scleroderma is an autoimmune disorder that affects the skin and internal organs and occurs when immune system malfunctions and starts attacking body’s own tissue and organs. Growing prevalence of systemic scleroderma is increasing the demand for therapies used to treat the symptoms and grant of supplemental approvals for existing treatment options along with the therapies that are under development are growing the demand in the market. For instance, in September 2020, U.S. FDA assigned, Orphan Drug Designation to Kadmon Holdings Inc. for its novel drug candidate, Belumosudil (KD025), which is developed for the treatment of systemic sclerosis. Similarly, in 2019, Boehringer Ingelheim International GmbH’s product - Ofev (nintedanib) – got approval from U.S. FDA for treatment of patients with Systemic Sclerosis with Interstitial Lung Disease (SSc-ILD). Furthermore, growing focus of biotechnology industries towards developing new therapies for the treatment of systemic scleroderma is expected to fuel the demand in coming years. However, lack of validated results and failure of clinical trials are expected to curb the growth during forecast period.

Among Asia Pacific, North America, Europe, Latin America, and Rest of the World, North America is the significant region across the world in terms of market share due to rising prevalence of systemic scleroderma in the region. Whereas Europe is anticipated to exhibit the highest growth rate over the forecast period 2021-2027, due to higher usage of generics and biosimilars for off-label systemic scleroderma therapy.

Major market player included in this report are:

Boehringer Ingelheim International GmbH

Gilead Sciences Inc.

GlaxoSmithKline plc

Novartis AG

Pfizer Inc.

Hoffmann La Roche Ltd.

Johnson & Johnson Services, Inc.

United Therapeutics

Eli Lilly and Company

Mylan N.V.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

Immunosuppressors

Phosphodiesterase 5 inhibitors - PHA

Endothelin Receptor Antagonists

Prostacyclin Analogues

Calcium Channel Blockers

Others

By Region:

North America

U.S.

Canada

Europe

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019

Base year – 2020

Forecast period – 2021 to 2027.

Target Audience of the Global Systemic Scleroderma Treatment Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Chapter 1. Executive Summary

1.1. Market Snapshot

1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)

1.2.1. Systemic Scleroderma Treatment Market, by Region, 2019-2027 (USD Billion)

1.2.2. Systemic Scleroderma Treatment Market, by Drug Class, 2019-2027 (USD Billion)

1.3. Key Trends

1.4. Estimation Methodology

1.5. Research Assumption

Chapter 2. Global Systemic Scleroderma Treatment Market Definition and Scope

2.1. Objective of the Study

2.2. Market Definition & Scope

2.2.1. Scope of the Study

2.2.2. Industry Evolution

2.3. Years Considered for the Study

2.4. Currency Conversion Rates

Chapter 3. Global Systemic Scleroderma Treatment Market Dynamics

3.1. Systemic Scleroderma Treatment Market Impact Analysis (2019-2027)

3.1.1. Market Drivers

3.1.1.1. Rising prevalence of systemic scleroderma

3.1.1.2. Grant of supplemental approvals to pharmaceutical companies

3.1.2. Market Restraint

3.1.2.1. Lack of validated results

3.1.2.2. Failure of clinical trials

3.1.3. Market Opportunities

3.1.3.1. Rising focus of biotechnology industry towards development of new therapies

Chapter 4. Global Systemic Scleroderma Treatment Market Industry Analysis

4.1. Porter’s 5 Force Model

4.1.1. Bargaining Power of Suppliers

4.1.2. Bargaining Power of Buyers

4.1.3. Threat of New Entrants

4.1.4. Threat of Substitutes

4.1.5. Competitive Rivalry

4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2027)

4.2. PEST Analysis

4.2.1. Political

4.2.2. Economical

4.2.3. Social

4.2.4. Technological

4.3. Investment Adoption Model

4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Systemic Scleroderma Treatment Market, by Drug Class

5.1. Market Snapshot

5.2. Global Systemic Scleroderma Treatment Market by Drug Class, Performance - Potential Analysis

5.3. Global Systemic Scleroderma Treatment Market Estimates & Forecasts by Drug Class 2018-2027 (USD Billion)

5.4. Systemic Scleroderma Treatment Market, Sub Segment Analysis

5.4.1. Immunosuppressors

5.4.2. Phosphodiesterase 5 inhibitors - PHA

5.4.3. Endothelin Receptor Antagonists

5.4.4. Prostacyclin Analogues

5.4.5. Calcium Channel Blockers

5.4.6. Others

Chapter 6. Global Systemic Scleroderma Treatment Market, Regional Analysis

6.1. Systemic Scleroderma Treatment Market, Regional Market Snapshot

6.2. North America Systemic Scleroderma Treatment Market

6.2.1. U.S. Systemic Scleroderma Treatment Market

6.2.1.1. Drug Class breakdown estimates & forecasts, 2018-2027

6.2.2. Canada Systemic Scleroderma Treatment Market

6.3. Europe Systemic Scleroderma Treatment Market Snapshot

6.3.1. U.K. Systemic Scleroderma Treatment Market

6.3.2. Germany Systemic Scleroderma Treatment Market

6.3.3. France Systemic Scleroderma Treatment Market

6.3.4. Spain Systemic Scleroderma Treatment Market

6.3.5. Italy Systemic Scleroderma Treatment Market

6.3.6. Rest of Europe Systemic Scleroderma Treatment Market

6.4. Asia-Pacific Systemic Scleroderma Treatment Market Snapshot

6.4.1. China Systemic Scleroderma Treatment Market

6.4.2. India Systemic Scleroderma Treatment Market

6.4.3. Japan Systemic Scleroderma Treatment Market

6.4.4. Australia Systemic Scleroderma Treatment Market

6.4.5. South Korea Systemic Scleroderma Treatment Market

6.4.6. Rest of Asia Pacific Systemic Scleroderma Treatment Market

6.5. Latin America Systemic Scleroderma Treatment Market Snapshot

6.5.1. Brazil Systemic Scleroderma Treatment Market

6.5.2. Mexico Systemic Scleroderma Treatment Market

6.6. Rest of The World Systemic Scleroderma Treatment Market

Chapter 7. Competitive Intelligence

7.1. Top Market Strategies

7.2. Company Profiles

7.2.1. Boehringer Ingelheim International GmbH

7.2.1.1. Key Information

7.2.1.2. Overview

7.2.1.3. Financial (Subject to Data Availability)

7.2.1.4. Product Summary

7.2.1.5. Recent Developments

7.2.2. Gilead Sciences Inc.

7.2.3. GlaxoSmithKline plc

7.2.4. Novartis AG

7.2.5. Pfizer Inc.

7.2.6. Hoffmann La Roche Ltd.

7.2.7. Johnson & Johnson Services, Inc.

7.2.8. United Therapeutics

7.2.9. Eli Lilly and Company

7.2.10. Mylan N.V.

Chapter 8. Research Process

8.1. Research Process

8.1.1. Data Mining

8.1.2. Analysis

8.1.3. Market Estimation

8.1.4. Validation

8.1.5. Publishing

8.2. Research Attributes

8.3. Research Assumption

List of Tables

TABLE 1. Global Systemic Scleroderma Treatment Market , report scope

TABLE 2. Global Systemic Scleroderma Treatment Market estimates & forecasts by region 2018-2027 (USD Billion)

TABLE 3. Global Systemic Scleroderma Treatment Market estimates & forecasts by Drug Class 2018-2027 (USD Billion)

TABLE 4. Global Systemic Scleroderma Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 5. Global Systemic Scleroderma Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 6. Global Systemic Scleroderma Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 7. Global Systemic Scleroderma Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 8. Global Systemic Scleroderma Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 9. Global Systemic Scleroderma Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 10. Global Systemic Scleroderma Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 11. Global Systemic Scleroderma Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 12. Global Systemic Scleroderma Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 13. Global Systemic Scleroderma Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 14. Global Systemic Scleroderma Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 15. Global Systemic Scleroderma Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 16. Global Systemic Scleroderma Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 17. Global Systemic Scleroderma Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 18. Global Systemic Scleroderma Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 19. Global Systemic Scleroderma Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)

TABLE 20. U.S. Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 21. U.S. Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 22. U.S. Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 23. Canada Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 24. Canada Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 25. Canada Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 26. UK Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 27. UK Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 28. UK Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 29. Germany Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 30. Germany Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 31. Germany Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 32. France Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 33. France Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 34. France Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 35. Spain Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 36. Spain Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 37. Spain Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 38. Italy Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 39. Italy Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 40. Italy Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 41. ROE Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 42. ROE Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 43. ROE Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 44. China Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 45. China Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 46. China Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 47. India Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 48. India Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 49. India Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 50. Japan Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 51. Japan Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 52. Japan Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 53. Australia Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 54. Australia Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 55. Australia Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 56. South Korea Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 57. South Korea Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 58. South Korea Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 59. ROPAC Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 60. ROPAC Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 61. ROPAC Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 62. Brazil Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 63. Brazil Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 64. Brazil Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 65. Mexico Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 66. Mexico Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 67. Mexico Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 68. ROLA Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 69. ROLA Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 70. ROLA Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 71. ROW Systemic Scleroderma Treatment Market estimates & forecasts, 2018-2027 (USD Billion)

TABLE 72. ROW Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 73. ROW Systemic Scleroderma Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)

TABLE 74. List of secondary sources used in the study of global Systemic Scleroderma Treatment Market .

TABLE 75. List of primary sources used in the study of global Systemic Scleroderma Treatment Market .

TABLE 76. Years considered for the study.

TABLE 77. Exchange rates considered.

Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Global Systemic Scleroderma Treatment Market Size study, by Drug Class (Immunosuppressors, Phosphodiesterase 5 inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers and Others), and Regional Forecasts 2021-2027

Contact Us

Drop Us an email at

Similar Reports

Client Testimonials

Maria

David

Sara